Tracking Cancer Evolution through the Disease Course.
Tracking Cancer Evolution through the Disease Course.
复制标题
DOI：
10.1158/2159-8290.cd-20-1559
复制
发表时间：
2021-04
期刊：
影响因子：
28.2
通讯作者：
Swanton C
中科院分区：
文献类型：
--
作者：
Bailey C;Black JRM;Reading JL;Litchfield K;Turajlic S;McGranahan N;Jamal-Hanjani M;Swanton C
在癌症进化过程中，肿瘤细胞在动态选择压力下竞争。表型变异可以观察为肿瘤内异质性，其通过基因组不稳定性传播，导致突变、体细胞拷贝数改变和表观基因组变化。 TRACERx 成立于 2014 年，旨在观察肿瘤内异质性与患者预后之间的关系。通过将原发性肿瘤的多区域测序与前瞻性招募的患者队列的纵向采样相结合，可以从早期到晚期疾病以及整个治疗过程中跟踪癌症的演变。在这里，我们回顾了这些研究的一些关键特征，并展望了该领域的未来。
During cancer evolution constituent tumour cells compete under dynamic selection pressures. Phenotypic variation can be observed as intratumour heterogeneity, which is propagated by genome instability leading to mutations, somatic copy number alterations and epigenomic changes. TRACERx was set up in 2014 to observe the relationship between intratumour heterogeneity and patient outcome. By integrating multi-region sequencing of primary tumours with longitudinal sampling of a prospectively recruited patient cohort, cancer evolution can be tracked from early to late stage disease and through therapy. Here we review some of the key features of the studies and look to the future of the field.